Free press releases distribution network?

Agency / Source: Bioo Scientific

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Bioo Scientific Launches A New Division - Bioo Therapeutics - Bioo Scientific launched Bioo Therapeutics to leverage their drug delivery vehicles and experience in antibody and small molecule research to develop therapeutic agents - BiooTherapeutics.com
Bioo Scientific Launches A New Division - Bioo Therapeutics

 

PRZOOM - /newswire/ - Austin, TX, United States, 2009/11/11 - Bioo Scientific launched Bioo Therapeutics to leverage their drug delivery vehicles and experience in antibody and small molecule research to develop therapeutic agents - BiooTherapeutics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioo Therapeutics, a division of Bioo Scientific, was launched today to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. Bioo Therapeutics flagship drug delivery technology is a patent pending antibody conjugation technology which delivers small RNA drugs into specifically targeted cells or tissues. The scientists at Bioo Scientific have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs by improving the loading capacity of antibody drug carriers and demonstrating their ability to successfully deliver small RNAs into tumors generated from cells expressing the cell surface target. Drugs or toxins can be attached to monoclonal antibodies which target a specific cell type forming monoclonal antibody conjugates. These monoclonal antibody conjugates are used as homing devices to deliver these substances directly into targeted cells. This patent pending technology can revolutionize the delivery of siRNA and other RNAi agents, as well as, other more traditional drugs.

"Bioo Therapeutics is actively seeking to partner with pharmaceutical companies or venture capitalists to make possible the therapeutic potential of this technology. This effort will advance targeted drug delivery which is vitally important for the development of new cures and treatments of cancer," said Lance Ford, VP of Research and Business Development for Bioo Scientific. This research is being supported by funding in part through grants from the National Science Foundation (NSF), the National Institute of Allergy and Infectious Disease (NIAID) and clients.

About Bioo Therapeutics

Bioo Therapeutics (biootherapeutics.com) is a division of Bioo Scientific, is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Therapeutics was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bioo Scientific

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioo Scientific Launches A New Division - Bioo Therapeutics

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dawn Obermoeller - BiooScientific.com 
512-301-4094 dawno[.]biooscientific.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioo Scientific securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Bioo Scientific / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  SKS Media | SKS Associates Ltd

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today